Ashvattha Therapeutics, Inc.

Ashvattha Therapeutics, Inc. company information, Employees & Contact Information

Explore related pages

Ashvattha Therapeutics, Inc. email format Ashvattha Therapeutics, Inc. management contacts

Related company profiles:

Ashvattha Therapeutics is developing a new class of drugs that identify and treat diseased cells with unprecedented precision. Our proprietary hydroxyl dendrimer (HD) platform, exclusively licensed from Johns Hopkins University, allows for the creation of hydroxyl dendrimer therapeutics (HDTs), which link known small molecule drugs to HDs for selective delivery with sustained effect in diseased tissues. We believe this approach to precision medicine has the potential to change the standard of care across neurology, ophthalmology, hyperinflammatory diseases and neuro-oncology.

Company Details

Employees
34
Founded
-
Address
1235 Radio Rd,
Phone
650-868-5853
Email
in****@****ics.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Website
avttx.com
Keywords
neurology, ophthalmology, inflammatory diseases, oncology.
HQ
Redwood City, California
Competitors
SpyGlass Pharma, Inc., Radionetics Oncology, Xseer Pharmaceuticals, Boiron Laboratories, Aerogen Pharma, Concuir Consulting, Perceive Biotherapeutics, Inc., McGuff Companies, Medicines360, ProQuality Network.
Looking for a particular Ashvattha Therapeutics, Inc. employee's phone or email?

Ashvattha Therapeutics, Inc. Questions

News

Ashvattha Therapeutics Appoints Ophthalmology Veteran Robert J. Dempsey as Interim CEO Following Positive Phase 2 Results and FDA Alignment on Pivotal Program - Yahoo Finance

Ashvattha Therapeutics Appoints Ophthalmology Veteran Robert J. Dempsey as Interim CEO Following Positive Phase 2 Results and FDA Alignment on Pivotal Program Yahoo Finance

Ashvattha Therapeutics to Present Phase 2 DME and nAMD Data at Innovate Retina - The Manila Times

Ashvattha Therapeutics to Present Phase 2 DME and nAMD Data at Innovate Retina The Manila Times

Ashvattha Therapeutics Subsidiary Orpheris Announces FDA Agreement to Initiate Phase 2 Study Evaluating OP-101 in Severe COVID-19 Patients - Business Wire

Ashvattha Therapeutics Subsidiary Orpheris Announces FDA Agreement to Initiate Phase 2 Study Evaluating OP-101 in Severe COVID-19 Patients Business Wire

Companies like Ashvattha Therapeutics, Inc.

Concuir Consulting logo - Similar company to Ashvattha Therapeutics, Inc.

Concuir Consulting

40
McGuff Companies logo - Similar company to Ashvattha Therapeutics, Inc.

Mcguff Companies

41
SpyGlass Pharma, Inc. logo - Similar company to Ashvattha Therapeutics, Inc.

Spyglass Pharma, Inc.

46
Xseer Pharmaceuticals logo - Similar company to Ashvattha Therapeutics, Inc.

Xseer Pharmaceuticals

20
Aerogen Pharma logo - Similar company to Ashvattha Therapeutics, Inc.

Aerogen Pharma

20
Boiron Laboratories logo - Similar company to Ashvattha Therapeutics, Inc.

Boiron Laboratories

46
ProQuality Network logo - Similar company to Ashvattha Therapeutics, Inc.

Proquality Network

15
Medicines360 logo - Similar company to Ashvattha Therapeutics, Inc.

Medicines360

42
Radionetics Oncology logo - Similar company to Ashvattha Therapeutics, Inc.

Radionetics Oncology

42
Perceive Biotherapeutics, Inc. logo - Similar company to Ashvattha Therapeutics, Inc.

Perceive Biotherapeu...

17

Top Ashvattha Therapeutics, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant